Search for Clinical Trial Results
Sarcoma, Ewing - 20 Studies Found
Status | Study |
Recruiting |
Study Name: First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years Condition: Ewing Sarcoma Family of Tumors Date: 2016-12-06 Interventions:
|
Terminated |
Study Name: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients Condition: Ewing's Sarcoma Date: 2002-05-29 Interventions:
|
Completed |
Study Name: Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Condition:
|
Available |
Study Name: Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma Condition: Ewing Sarcoma Date: 2017-01-20 Interventions: Drug: Ganitumab The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clin |
Withdrawn |
Study Name: Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Condition: Ewing's Sarcoma Date: 2012-11-19 Interventions: Radiation: External Beam Radiotherapy |
Recruiting |
Study Name: Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma Condition: Ewing Sarcoma Date: 2013-05-08 Interventions:
|
Recruiting |
Study Name: Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Condition: Ewing's Sarcoma Date: 2016-04-04 Interventions: Biological: pbi-shRNA™ EWS/FLI1 Type 1 LPX Other Name: pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex |
Completed |
Study Name: Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Condition: Ewing's Sarcoma Date: 2012-04-18 Interventions: Drug: Olaparib 400mg PO BID Continuous Other Name: A |
Recruiting |
Study Name: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma Condition: Ewing Sarcoma Date: 2014-01-21 Interventions:
|
Recruiting |
Study Name: Protocol for the Treatment of Metastatic Ewing Sarcoma Condition: Ewing's Sarcoma (ES) Date: 2016-03-23 Interventions:
|